To determine the association between the use of anticholinergic drugs and the risk of falls with hip fracture in a population older than 60 years.
Methods:
A case–control study in patients older than 60 years with a diagnosis of hip fracture. All drugs dispensed during the previous 30 days were identified. Sociodemographic, clinical, pharmacological (drugs according to the Anticholinergic Risk Scale [ARS]), and polypharmacy variables were analyzed.
Measurements:
Falls with hip fracture and type of drug according to the ARS.
Results:
A total of 300 patients with hip fracture and 600 controls were included. The mean age was 81.6 ± 8.9 years, with female predominance (71.3%). The use of drugs with moderate (odds ratio [OR]: 1.97, 95% confidence interval [CI]: 1.19-3.27) or high ARS scores (OR: 1.83, 95% CI: 1.13-2.96) increased the probability of fracture.
Conclusions:
There was an association between the use of drugs with anticholinergic properties and the probability of hip fracture in elderly patients and it was possible to establish the level of risk.
KingMLipskyMS. Clinical implications of aging. Dis Mon. 2015;61(11):467–474.
3.
YaylaEMYavuzEBilgeUKeskinABinenE. Drugs with anticholinergic side-effects in primary care. Niger J Clin Pract. 2015;18(1):18–21.
4.
BerdotSBertrandMDartiguesJF. Inappropriate medication use and risk of falls—a prospective study in a large community-dwelling elderly cohort. BMC Geriatr. 2009;9:30.
5.
Machado-AlbaJECastro-RodriguezAAlzate-PiedrahitaJAHoyos-PulgarinJAMedina-MoralesDA. Anticholinergic risk and frequency of anticholinergic drug prescriptions in a population older than 65. J Am Med Dir Assoc. 2016;17(3):275.e1–e4.
6.
OndaMImaiHTakadaYFujiiSShonoTNanaumiY. Identification and prevalence of adverse drug events caused by potentially inappropriate medication in homebound elderly patients: a retrospective study using a nationwide survey in Japan. BMJ Open. 2015;5(8):e007581.
7.
WillcoxSMHimmelsteinDUWoolhandlerS. Inappropriate drug prescribing for the community-dwelling elderly. JAMA. 1994;272(4):292–296.
8.
CollamatiAMartoneAMPosciaA. Anticholinergic drugs and negative outcomes in the older population: from biological plausibility to clinical evidence. Aging Clin Exp Res. 2016;28(1):25–35.
9.
CrispoJAWillisAWThibaultDP. Associations between anticholinergic burden and adverse health outcomes in Parkinson disease. PLoS One. 2016;11(3):e0150621.
10.
MangoniAAvan MunsterBCWoodmanRJde RooijSE. Measures of anticholinergic drug exposure, serum anticholinergic activity, and all-cause postdischarge mortality in older hospitalized patients with hip fractures. Am J Geriatr Psychiatry. 2013;21(8):785–793.
11.
SalahudeenMSHilmerSNNishtalaPS. Comparison of Anticholinergic Risk Scales and associations with adverse health outcomes in older people. J Am Geriatr Soc. 2015;63(1):85–90.
12.
VestergaardPRejnmarkLMosekildeL. Fracture risk associated with parkinsonism and anti-Parkinson drugs. Calcif Tissue Int. 2007;81(3):153–161.
13.
RudolphJLSalowMJAngeliniMCMcGlincheyRE. The Anticholinergic Risk Scale and anticholinergic adverse effects in older persons. Arch Intern Med. 2008;168(5):508–513.
14.
AizenbergDWeizmanAWeissAAkopianMAmitaiMBelooseskyY. The association in elderly hospitalized patients, between psychotropic drugs and hip fractures resulting from falls. Exp Aging Res. 2015;41(5):546–555.
15.
FraserLAAdachiJDLeslieWD. Effect of anticholinergic medications on falls, fracture risk, and bone mineral density over a 10-year period. Ann Pharmacother. 2014;48(8):954–961.
16.
LandiFDell’AquilaGCollamatiA. Anticholinergic drug use and negative outcomes among the frail elderly population living in a nursing home. J Am Med Dir Assoc. 2014;15(11):825–829.
17.
MarcumZAPereraSThorpeJM. Anticholinergic use and recurrent falls in community-dwelling older adults: findings from the health ABC study. Ann Pharmacother. 2015;49(11):1214–1221.
18.
SalahudeenMSDuffullSBNishtalaPS. Anticholinergic burden quantified by Anticholinergic Risk Scales and adverse outcomes in older people: a systematic review. BMC Geriatr. 2015;15:31.
19.
Morales-TorresJGutiérrez-UreñaS; Osteoporosis Committee of Pan-American League of Associations for Rheumatology. The burden of osteoporosis in Latin America. Osteoporos Int. 2004;15(8):625–632.
20.
OrcesCH. Epidemiology of hip fractures in Ecuador. Rev Panam Salud Publica. 2009;25(5):438–442.
21.
DhanwalDKDennisonEMHarveyNCCooperC. Epidemiology of hip fracture: worldwide geographic variation. Indian J Orthop. 2011;45(1):15–22.
22.
MeltonLJ III. Who has osteoporosis? A conflict between clinical and public health perspectives. J Bone Miner Res. 2000;15(12):2309–2314.
23.
LuWHWenYWChenLKHsiaoFY. Effect of polypharmacy, potentially inappropriate medications and anticholinergic burden on clinical outcomes: a retrospective cohort study. CMAJ. 2015;187(4):E130–E137.
24.
FreelandKNThompsonANZhaoYLealJEMauldinPDMoranWP. Medication use and associated risk of falling in a geriatric outpatient population. Ann Pharmacother. 2012;46(9):1188–1192.
25.
ZiaAKamaruzzamanSBTanMP. Polypharmacy and falls in older people: balancing evidence-based medicine against falls risk. Postgrad Med. 2015;127(3):330–337.
26.
KojimaTAkishitaMNakamuraT. Polypharmacy as a risk for fall occurrence in geriatric outpatients. Geriatr Gerontol Int. 2012;12(3):425–430.
27.
LaiSWLiaoKFLiaoCCMuoCHLiuCSSungFC. Polypharmacy correlates with increased risk for hip fracture in the elderly: a population-based study. Medicine (Baltimore). 2010;89(5):295–299.
28.
ArbouwMEMovigKLvan StaaTPEgbertsACSouvereinPCde VriesF. Dopaminergic drugs and the risk of hip or femur fracture: a population-based case-control study. Osteoporos Int. 2011;22(7):2197–2204.
29.
HungSCLinCHHungHCLinCLLaiSW. Use of selective serotonin reuptake inhibitors and risk of hip fracture in the elderly: a case-control study in Taiwan. J Am Med Dir Assoc. 2017;18(4):350–354.
30.
PacherPUngvariZ. Selective serotonin-reuptake inhibitor antidepressants increase the risk of falls and hip fractures in elderly people by inhibiting cardiovascular ion channels. Med Hypotheses. 2001;57(4):469–471.
31.
EhrtUBroichKLarsenJPBallardCAarslandD. Use of drugs with anticholinergic effect and impact on cognition in Parkinson’s disease: a cohort study. J Neurol Neurosurg Psychiatry. 2010;81(2):160–165.
32.
SittironnaritGAmesDBushAI; AIBL research group. Effects of anticholinergic drugs on cognitive function in older Australians: results from the AIBL study. Dement Geriatr Cogn Disord. 2011;31(3):173–178.
33.
HaneyEMChanBKDiemSJ; Osteoporotic Fractures in Men Study Group. Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men. Arch Intern Med. 2007;167(12):1246–1251.
34.
CrewsMPHowesOD. Is antipsychotic treatment linked to low bone mineral density and osteoporosis? A review of the evidence and the clinical implications. Hum Psychopharmacol. 2012;27(1):15–23.
35.
PouwelsSvan StaaTPEgbertsACLeufkensHGCooperCde VriesF. Antipsychotic use and the risk of hip/femur fracture: a population-based case-control study. Osteoporos Int. 2009;20(9):1499–1506.
36.
SorensenHJJensenSONielsenJ. Schizophrenia, antipsychotics and risk of hip fracture: a population-based analysis. Eur Neuropsychopharmacol. 2013;23(8):872–878.
37.
WilhelmSMRjaterRGKale-PradhanPB. Perils and pitfalls of long-term effects of proton pump inhibitors. Expert Rev Clin Pharmacol. 2013;6(4):443–451.
38.
Cardona-OspinaJMedina-MoralesDARodríguez-MoralesAMachado-AlbaJ. Efectos adversos a largo plazo de los inhibidores de la bomba de protones. Perspectiva desde la medicina basada en la evidencia. Rev Col Gastroenterol. 2017;31(4):403–408.
39.
KwokCSYeongJKLokeYK. Meta-analysis: risk of fractures with acid-suppressing medication. Bone. 2011;48(4):768–776.
40.
van der HoornMMTettSEde VriesOJDobsonAJPeetersGM. The effect of dose and type of proton pump inhibitor use on risk of fractures and osteoporosis treatment in older Australian women: a prospective cohort study. Bone. 2015;81:675–682.
41.
MobergLMNilssonPMSamsioeGBorgfeldtC. Use of proton pump inhibitors (PPI) and history of earlier fracture are independent risk factors for fracture in postmenopausal women. The WHILA study. Maturitas. 2014;78(4):310–315.
